Novadip

Novadip reports key nonclinical and interim clinical data for NVDX3, its off-the-shelf allogenic product,in spine fusion

NVDX3 elicited bone formation as early as 12 weeks and functional fusion by 26 weeks in ovine posterolateral fusion (PLF) model In phase 1b/2a clinical trial, early bone fusion was observed at 12 months, coupled with no NVDX3-related adverse events, in patients who had single-level lumbar spine fusion Phase 2b/3 trial in level two cervical...
Watson & Crick Hill, Rue Granbonpré 11, 1435 Mont-Saint-Guibert, Belgium

+32 (10) 779 220